Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages

Cancer Research

Volumn 66, Issue 21, 2006, Pages 10576-10585

  Romieu Mourez, Raphaëlle ^a   Solis, Mayra ^a   Nardin, Alessandra ^c   Goubau, Delphine ^a   Baron Bodo, Véronique ^c   Lin, Rongtuan ^a   Massie, Bernard ^b   Salcedo, Margarita ^c   Hiscott, John ^a  

^a MCGILL UNIVERSITY   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^c Immuno Designed Molecules   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; GELATINASE A; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 6; MESSENGER RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN;

ADENOVIRUS VECTOR; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CELL DEATH; CELL DIFFERENTIATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTIGENS, CD80; APOPTOSIS; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INTERFERON REGULATORY FACTOR-3; INTERFERON REGULATORY FACTOR-7; INTERFERON TYPE I; INTERLEUKIN-15; MACROPHAGE ACTIVATION; MACROPHAGES; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC;

EID: 33751301603     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1279     Document Type: Article

References (54)

1. Klimp AH, de Vries EG, Scherphof GL, Daemen T. A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hematol 2002;44:143-61.
2. Pages F, Lebel-Binay S, Vieillefond A, et al. Local immunostimulation induced by intravesical administration of autologous interferon-7-activated macrophages in patients with superficial bladder cancer. Clin Exp Immunol 2002;127:303-9.
3. Thiounn N, Pages F, Mejean A, Descotes JL, Fridman WH, Romet-Lemonne JL. Adoptive immunotherapy for superficial bladder cancer with autologous macrophage activated killer cells. J Urol 2002;168:2373-6.
4. Monnet I, Breau JL, Moro D, et al. Intrapleural infusion of activated macrophages and γ-interferon in malignant pleural mesothelioma: a phase II study. Chest 2002;121:1921-7.
5. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5:375-86.
6. Katze MG, He Y, Gale M, Jr. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002;2:675-87.
7. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006;7:131-7.
8. Servant MJ, ten Oever B, Lin R. Review overlapping and distinct mechanisms regulating IRF-3 and IRF-7 function. J Interferon Cytokine Res 2002;22:49-58.
9. Fitzgerald KA, McWhirter SM, Faia KL, et al. IKKε and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003;4:491-6.
10. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science 2003;300:1148-51.
11. Maniatis T, Falvo JV, Kim TH, et al. Structure and function of the interferon-β enhanceosome. Cold Spring Harb Symp Quant Biol 1998;63:609-20.
12. Civas A, Genin P, Morin P, Lin R, Hiscott J. Promoter organization of the interferon-A genes differentially affects virus-induced expression and responsiveness to TBK1 and IKKε. J Biol Chem 2006;281:4856-66.
13. Marie I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-α genes by positive feedback through interferon regulatory factor-7. EMBO J 1998;17:6660-9.
14. Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-1 interferon-dependent immune responses. Nature 2005;434:772-7.
15. Barnes BJ, Richards J, Mancl M, Hanash S, Beretta L, Pitha PM. Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection. J Biol Chem 2004;279:45194-207.
16. Lin R, Heylbroeck C, Pitha PM, Hiscott J. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol Cell Biol 1998;18:2986-96.
17. Lin R, Mamane Y, Hiscott J. Structural and functional analysis of interferon regulatory factor 3: localization of the transactivation and autoinhibitory domains. Mol Cell Biol 1999;19:2465-74.
18. Lin R, Mamane Y, Hiscott J. Multiple regulatory domains control IRF-7 activity in response to virus infection. J Biol Chem 2000;275:34320-7.
19. Lin R, Genin P, Mamane Y, Hiscott J. Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of α/β interferon genes by interferon regulatory factors 3 and 7. Mol Cell Biol 2000;20:6342-53.
20. Massie B, Couture F, Lamoureux L, et al. Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. J Virol 1998;72:2289-96.
21. Mullick A, Xu Y, Warren R. The cumate gene-switch: a system for regulated expression in mammalian cells. BMC Biotech. In press 2006.
22. Elahi SM, Oualikene W, Naghdi L, O'Connor-McCourt M, Massie B. Adenovirus-based libraries: efficient generation of recombinant adenoviruses by positive selection with the adenovirus protease. Gene Ther 2002;9:1238-46.
23. Ogorelkova M, Elahi SM, Gagnon D, Massie B. DNA delivery to cells in culture: generation of adenoviral libraries for high-throughput functional screening. Methods Mol Biol 2004;246:15-27.
24. Rebel VI, Hartnett S, Denham J, Chan M, Finberg R, Sieff CA. Maturation and lineage-specific expression of the coxsackie and adenovirus receptor in hematopoietic cells. Stem Cells 2000;18:176-82.
25. Baron-Bodo V, Doceur P, Lefebvre ML, et al. Anti-tumor properties of human-activated macrophages produced in large scale for clinical application. Immunobiology 2005;210:267-77.
26. Genin P, Algarte M, Roof P, Lin R, Hiscott J. Regulation of RANTES chemokine gene expression requires cooperativity between NF-κB and IFN-regulatory factor transcription factors. J Immunol 2000;164:5352-61.
27. Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003;4:263-75.
28. Remoli ME , Giacomini E, Lutfalla G, et al. Selective expression of type I IFN genes in human dendritic cells infected with mycobacterium tuberculosis. J Immunol 2002;169:366-74.
29. Heylbroeck C, Balachandran S, Servant MJ, et al. The IRF-3 transcription factor mediates Sendai virus-induced apoptosis. J Virol 2000;74:3781-92.
30. Grandvaux N, Gaboriau F, Harris J, tenOever BR, Lin R, Hiscott J. Regulation of arginase II by interferon regulatory factor 3 and the involvement of polyamines in the antiviral response. FEBS J 2005;272:3120-31.
31. Salkowski CA, Thomas KE, Cody MJ, Vogel SN. Impaired IFN-γ production in IFN regulatory factor-1 knockout mice during endotoxemia is secondary to a loss of both IL-12 and IL-12 receptor expression. J Immunol 2000;165:3970-7.
32. Walker W, Aste-Amezaga M, Kastelein RA, Trinchieri G, Hunter CA. IL-18 and CD28 use distinct molecular mechanisms to enhance NK cell production of IL-12-induced IFN-γ. J Immunol 1999;162:5894-901.
33. Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003;424:516-23.
34. Azimi N, Shiramizu KM, Tagaya Y, Mariner J, Waldmann TA. Viral activation of interleukin-15 (IL-15): characterization of a virus-inducible element in the IL-15 promoter region. J Virol 2000;74:7338-48.
35. Kirshner JR, Karpova AY, Kops M, Howley PM. Identification of TRAIL as an interferon regulatory factor 3 transcriptional target. J Virol 2005;79:9320-4.
36. Sato K, Hida S, Takayanagi H, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-α/β. Eur J Immunol 2001;31:3138-46.
37. Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J 2004;23:3051-60.
38. De Stefano D, Maiuri MC, Iovine B, Ialenti A, Bevilacqua MA, Carnuccio R. The role of NF-κB, IRF-1, and STAT-1α transcription factors in the iNOS gene induction by gliadin and IFN-γ in RAW 264.7 macrophages. J Mol Med 2006;84:65-74. Epub 2005 Nov 12.
39. Boyer A, Andreu G, Romet-Lemonne JL, Fridman WH, Teillaud JL. Generation of phagocytic MAK and MAC-DC for therapeutic use: characterization and in vitro functional properties. Exp Hematol 1999;27:751-61.
40. Huang SF, Kim SJ, Lee AT, et al. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-α-2b and docetaxel. Cancer Res 2002;62:5720-6.
41. Wu WZ, Sun HC, Shen YF, et al. Interferon α 2a down-regulates VEGF expression through P13 kinase and MAP kinase signaling pathways. J Cancer Res Clin Oncol 2005;131:169-78.
42. Oliveira IC, Sciavolino PJ, Lee TH, Vilcek J. Down-regulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci U S A 1992;89:9049-53.
43. Duguay D, Mercier F, Stagg J, et al. In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors. Cancer Res 2002;62:5148-52.
44. Dunn GP, Bruce AT, Sheehan KC, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005;6:722-9.
45. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999;5:1249-55.
46. Luft T, Pang KC, Thomas E, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998;161:1947-53.
47. Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K, Fukuhara S. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol 2001;166:2961-9.
48. Montoya M, Schiavoni G, Mattel F, et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 2002;99:3263-71.
49. Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res 2003;90:127-56.
50. + T cells stimulated by virus-induced type I interferon. Nat Immunol 2003;4:1009-15.
51. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001;14:461-70.
52. Lu R, Pitha PM. Monocyte differentiation to macrophage requires interferon regulatory factor 7. J Biol Chem 2001;276:45491-6.
53. Dauer M, Schad K, Junkmann J, et al. IFN-α promotes definitive maturation of dendritic cells generated by short-term culture of monocytes with GM-CSF and IL-4. J Leukoc Biol 2006;80:278-86. Epub 2006 Jun 12.
54. Svane IM, Nikolajsen K, Walter MR, et al. Characterization of monocyte-derived dendritic cells maturated with IFN-α. Scand J Immunol 2006;63:217-22.